PFE vs PPBT

Pfizer Inc. remains a mature, large-cap pharmaceutical company with limited potential for the requested 10x growth within 3-5 years, which would require a market cap exceeding $1.4 trillion. While Q1 2026 results showed revenue of $14.45B and adjusted EPS of $0.75, both beating estimates, YoY revenue growth was modest at +5.4% and adjusted EPS declined -18%. Strategic legal wins for VYNDAQEL and C...

Purple Biotech presents a compelling high-risk, high-reward opportunity in oncology with a 10x potential driven by its novel CAPTN-3 tri-specific antibody platform progressing towards IND (expected Q4 2026) and two Phase 2 assets primed for partnerships. The Q1 2026 results showed a significantly narrower net loss (beating consensus by $0.29) and a controlled adjusted operating loss of $2.1 millio...